Trex Bio Inc. has closed an oversubscribed $84 million series B financing round to support development of its pipeline of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
Trex Bio Inc. has announced its selection of a new development candidate, TRB-061, designed to selectively agonize TNF receptor 2 (TNFR2), a mechanism with potential across a broad range of autoimmune indications.
Trex Bio Inc. has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly & Co. to develop novel therapies for the treatment of immune-mediated diseases.
Trex Bio Inc., which kicked off 2022 with a big pharma partnership, is back at it again, starting the new year with a potential $1.1 billion agreement with original backer Eli Lilly and Co. targeting immune-mediated diseases. Under the terms, Trexbio gets $55 million up front, with Lilly picking up an exclusive worldwide license for candidates from three programs.
